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THE FDA BLACK BOX WARNING SYSTEM: THE UTMOST IN DRUG AND PATIENT 
SAFETY? Andrew Georgi (Sponsored by Paul Barash, MD, and Loreta Grecu, MD).  
Department of Anesthesiology, Yale University School of Medicine, New Haven, CT. 
Of the 7856ψ pharmaceutical products under the purview of the Food and Drug 
Administration (FDA), over six hundred have a black box warning (BBW). As the FDA’s highest 
level of warning included on drug package inserts, this notation is reserved for those drugs that 
pose significant risks leading to “death or serious injury”. However, the types of warnings that 
warrant this distinction have not been clearly identified and are not always readily justifiable.  In 
addition, great variability exists among the drugs resources charged with transmitting this critical 
information to healthcare professionals and the public. 
The objective of this paper is to establish the most comprehensive list of drugs with a 
BBW, classify their content according to organ systems, and in doing so evaluate the consistency 
of information presented by these widely-used drug resources. This was accomplished by cross-
referencing and analyzing the drug BBW information from four resources: DailyMed, 
Micromedex, Facts & Comparisons, and BlackBoxRx.  
 Six hundred and thirty-five drug/drug combinations were identified as having a BBW. 
The most frequently affected organ systems were cardiovascular and pulmonary with 200/635 
and 144/635 drug BBWs, respectively. DailyMed was the most comprehensive list with 551/635 
drugs, still a shortfall of 13%. The four lists were in complete agreement for 416/635 (65%) of 
the drugs listed. This highlights the FDA’s need to review the black box warning system and 
determine how best to communicate this drug information accurately and efficiently to the 
healthcare community.
                                               
ψ Refers to the number of distinct clinical drugs and packs (both generic and 
branded) contained in the NLM website dailymed.nlm.nih.gov. Provided on 4/13/10 by Dr. Stuart Nelson, 
Head of Medical Subject Headings at the National Library of Medicine. 
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Understanding the purpose and station of the black box warning (BBW) first 
requires an exploration of its origins and the organization responsible for its 
development: The Food and Drug Administration (FDA).  
Although the Food and Drug Act was not signed into law until 1906, the FDA’s 
birth can be dated back to 1862 when Abraham Lincoln appointed a single individual, 
Charles Wetherell, to the Department of Chemistry. This modest beginning stands in 
stark contrast to the sizeable organization into which the FDA has grown. A subsidiary of 
the Department of Health and Human Services, the Food and Drug Administration has 
more than 11,000 employees and an annual working budget of over $2.5 billion. (1) Its 
regulatory responsibilities include governing “the safety and purity” of products that 
range from the U.S. food supply, nutritional supplements, and cosmetics to vaccines, 
medical devices, blood products, and pharmaceuticals.  This equates to oversight of over 
$1 trillion worth of products each year, or 25 cents of every dollar spent by American 
consumers. (2,3) The Center for Drug Evaluation and Research (CDER) is a subdivision 
of the FDA with over 2200 employees, mostly physicians and scientists, whose chief 
responsibility it is to regulate the pharmaceutical industry and act as “America’s 
consumer watchdog for medicines.” (4)  
FDA approval of pharmaceuticals is a complicated and lengthy endeavor 
requiring intensive animal studies on toxicity and pharmacologic activity which the FDA 
must review before a drug can even be considered for initial study in humans.  From 
there it must successfully navigate three phases of clinical trials used to assess adverse 
reactions, safe dosing, drug kinetics, and later its efficacy in target populations with 
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selected indication(s) for which the drug seeks approval.  The FDA in turn must evaluate 
whether or not these collected data demonstrate that the drug is safe and effective for its 
intended use and that adequate and appropriate directions and precautions are portrayed 
in the drug’s labeling. In certain instances, such as when a new drug class is introduced or 
a drug seeking approval carries significant safety risks, an Advisory Committee of 
outside experts may be convened to establish the conditions of approval and any 
accompanying special labeling. (4) 
All FDA approved drugs require labeling which can be found on the product 
container, packaging, and an accompanying document referred to as the “package insert” 
or “product information”. It is noteworthy to point out that this drug labeling is written by 
the pharmaceutical companies, but must undergo negotiation and approval by the FDA. 
The drug labeling should be “a summary of essential scientific information needed for 
safe and effective use of the drug. It should be informative, accurate, and neither 
promotional in tone nor false or misleading, and should be based on data derived from 
human experience whenever possible.” (4) This involves incorporating all clinically 
relevant information pertaining to that drug including any contraindications, adverse 
reactions, warnings, or precautions.  The information contained within the package insert 
can also be found in prescribing texts such as the Physicians’ Desk Reference (PDR), 
PDA & smartphone software programs, and online resources, some of which will be 
described later. In fact, the FDA now requires that pharmaceutical companies file all 
prescription labels electronically. (5) 
The first drug label appeared with isoproterenol, which in 1968 consisted of a two 
line warning on the inhaler package. (3) Over the years the product label has become 
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much more extensive and complex, making its navigation by clinicians and patients much 
too difficult and time-consuming to be of real value. This led the FDA to revisit how 
these inserts were formatted and establish a more concise and orderly way of presenting 
the information in 2006, a format to which all newly approved drugs must adhere. (3) 
The purpose of the new format was to not only make the information more readable and 
accessible, but also to highlight the most critical clinical information in an appropriate 
manner. Each package insert is divided into three major sections: 
1. The Highlights of Prescribing Information 
2. Full Prescribing Information Table of Contents 
3. The Full Prescribing Information 
As all drugs are associated with a variety of adverse effects, a description of these 
effects is an essential component of the drug label so that the individual clinician and 
patient can weigh the potential benefits against these risks. In each section, risks 
associated with a drug are presented in descending order of importance and severity. (6) 
As the FDA’s utmost cautionary statement, the black box warning appears at the very 
beginning of the package insert in the “Highlights of Prescribing Information” just below 
the drug name and year of approval. It appears again at the beginning of the “Full 
Prescribing Information” section. Aptly named, the BBW must also be bolded with a 
heading in all caps, and a solid black line on all four sides constituting the box. (3) It is 
issued only for “the most serious warnings necessary to ensure the continued safe use of 
the product”, (7) and is the highest level of five possible warnings that the FDA can 
require in the package insert. (8) While the pharmaceutical company writes the contents 
of the drug labeling, it cannot unilaterally decide to include a BBW. The ability to issue a 
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BBW is reserved by the FDA. (7) Following the 2007 FDA Amendments Act (FDAAA), 
the FDA also has the power to mandate labeling changes, including BBWs. (9) 
Despite its initial appearance in the PDR with Choramphenicol fifteen years earlier, 
the “boxed warning” or “black box warning” was not introduced as an official part of the 
package insert in 1979. (3,9) The Code of Federal Regulations stipulated that “special 
problems, particularly those that may lead to death or serious injury, may be required by 
the Food and Drug Administration to be placed in a prominently displayed box. The 
boxed warning ordinarily shall be based on clinical data, but serious animal toxicity may 
also be the basis of a boxed warning in the absence of clinical data.” (7) However, 
exactly how these “special problems” were identified or specifically what level of proof 
was necessary remained unclear. In 1998 to address this, Beach et al. published their own 
research reviewing 206 drugs with BBWs in an attempt to identify what situations 
resulted in the FDA mandating a BBW. (6) They concluded that six such situations 
existed: 
1. “early detection of a side effect by physicians may result in intervention that may 
reverse the adverse reaction; 
2. a well-defined subset of patients are at higher risk for the treatment; 
3. the risk from the treatment of the particular drug may outweigh the benefits in 
particular circumstances; 
4. the dosing or drug interaction is pivotal to the risk; 
5. the training of the physician or the setting is crucial; and 
6. there are other special requirements for administering the drug” 
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Eight years later, the FDA subsequently issued general guidelines, still in effect, that 
identify three situations which require a BBW:  
1.”There is an adverse reaction so serious in proportion to the potential benefit from 
the drug that it is essential that it be considered in assessing the risks and benefits of 
using the drug. This includes potentially life threatening or permanently disabling 
adverse reactions. 
2. There is a serious reaction that can be prevented or reduced in frequency or 
severity by patient selection, careful monitoring, avoiding certain concomitant 
therapy, addition of another drug or managing patient in a specific manner, or 
avoiding use in a specific clinical situation. 
3. The FDA approved the drug with restrictions on use and distribution to assure safe 
use.” (1)  
These guidelines, however, still fail to delineate a standardized approach or formulaic 
manner by which a drug is labeled with a BBW. This has lead many clinicians to 
question the accuracy and utility of the FDA’s most stringent warning. Indeed, physician 
compliance to prescribing recommendations found in BBWs can be highly variable. (10)  
Notwithstanding this uncertainty that surrounds the BBW, its effects are felt at all 
levels of the healthcare totem from the pharmaceutical manufacturer, to clinician, 
pharmacist, and on to the patient; and despite its black hue, it can often have the effect of 
a “scarlet letter”. For example, the package insert is not the only material required to 
display the BBW. The pharmaceutical company must include it in all promotional items 
such as magazine/TV/radio advertisements, exhibits, booklets, literature, or any other 
material that describes the drug’s use by medical professionals. (7) This restricted 
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advertising and arguably negative publicity can affect sales as both practitioners and 
patients may be less inclined to use the drug. Physicians potentially bear the brunt of 
lawsuits from patients who do experience adverse reactions set forth in the BBW as some 
courts have ruled these warning adequately advise the physician of the drug’s associated 
risks, thus protecting the pharmaceutical company from product liability. (6) This may 
cause physicians to turn to drugs with which they are less familiar, which carry their own 
side effect profile, and perhaps are more costly, thus adversely affecting the patient. (7) 
This indeed was the case with droperidol which will be discussed later. Issuance of a 
BBW may even result in patient noncompliance to the therapy. (11) 
Despite its potential and realized shortcomings, the BBW may still represent the 
hereto best method to summarize the most severe adverse reactions pursuant to patient 
safety. It has been referred to as the “FDA’s primary instrument to protect the public 
from potentially dangerous effects of medicines”. (10) While only 635/7856α drugs have 
a BBW, they still make-up a considerable amount of prescriptions filled. Looking at a 
sample population of nearly one million patients, Wagner et al. concluded that over 40% 
of ambulatory care patients had been prescribed at least one BBW medication during the 
30-month study period. (10) Because these warnings are, as a rule, reserved for only the 
most serious reactions that often can be prevented or reduced with appropriate drug use, 
failed awareness or respect for their content can be costly. The Institute of Medicine 
reports 400,000 in-hospital adverse drug reactions per year at a cost of $3.5 billion. (3) It 
can be extrapolated that misuse of drugs with BBWs may account for a significant 
portion of these though no actual data exists that can verify this. 
                                               
α See methods for definition of how drugs with a BBW were quantified 
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Since the majority of BBWs are introduced following post-marketing surveillance 
(e.g. MedWatch), clear, timely, and effective communication of these and other adverse 
reactions to clinicians is of paramount importance. (7) However, efforts to do so have not 
always been effective. (10) With the enormous repository, steady influx, and continuous 
modifications of medications, physicians face a daunting challenge of keeping pace. In 
this digital age, fewer patients and healthcare providers actually refer to the package 
inserts themselves to obtain detailed drug information and instead seek out electronic 
resources. Numerous resources, publicly and privately funded, free and fee-based, 
percolate the internet or come packaged in software for PDAs and smartphones. Web-
based drug databases such as Micromedex (12), Facts & Comparisons (13), and 
DailyMed (14) endeavor to supply comprehensive and updated drug information.β 
However, even DailyMed, a multimillion dollar federally funded project and storehouse 
for the FDA mandated electronic product labels, has the disclaimer that it “does not 
contain a complete listing of labels for approved prescription drugs.” (15) 
This begs the following questions: If the FDA does not profess to house the entirety 
of records for the pharmaceutical products it regulates, in particular those products that 
carry its most severe warning, where can these be found? Also, with increasing time 
constraints and demands in clinical practice and the overwhelming amount of information 
presented even in these black box warnings, how can the practitioner stay readily 
informed of the multifaceted effects these cautionary statements forewarn for their 
patients?   
                                               
β A more detailed description of these three web-based drug resources which were used along with a fourth 
resource, BlackBoxRx, for the BBW drug information presented in this thesis research will be provided 
later. 
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Statement of Purpose: 
The purpose of this paper is to identify all drugs that contain a black box warning 
and classify these warnings in tabulated form by organ systems. Warnings that did not 
fall under this umbrella, including drug interactions, administration instructions, and 
cautionary statements for specific targeted populations, were also classified on the table, 
accordingly. The data gathered were also used to identify the frequency of the warning 
classifications found in the BBW drugs. In addition, the resources utilized in compilation 
of the BBW table were evaluated for relative comprehensiveness and consistency with 
respect to each other and the collective BBW list they were used to create. 
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Methods:  
A literature search was performed from July 2009-February 2010 via PubMed 
using the terms “black box warning”, “boxed warning”, and “warning classification” to 
identify any previous publications of black box warnings classified in the manner. No 
such articles were identified.  
For the purpose of this paper, online drug resources were selected based on ease 
of access to black box warning information, perceived use by physicians and pharmacists, 
and availability to the general public. Four web-based drug databases were identified: 
DailyMed (14), Micromedex (12), Facts & Comparisons (13), and BlackBoxRx (16) 
(formerly FormWeb). An illustration of the format in which black box warning 
information was presented in each of these resources is included. (Figures 1-4) 
(17,18,19,20) A more detailed discussion of the perceived strengths and weaknesses of 
each database will be discussed later.  
First, a collective list of all drugs with BBW labels as found in these four 
resources was compiled. This combined list will be referred to as the “collective BBW 
list”. Three of the electronic drug resources provided a separate distinct list of all drugs 
that contained a black box warning in their respective databases.(16,21,22) Of the four, 
DailyMed was the only resource which had no such list available; as such, assistance was 
proved by Dr. Stuart Nelson, Head of Medical Subject Headings at the National Library 
of Medicine (NLM), to analyze the downloadable XML-based Structured Product 
Labeling (SPL) found in DailyMed. The SPL content was utilized to create a distinct 
BBW list in spreadsheet format for DailyMed. (23) Each drug SPL in DailyMed that 
contained a tag for a black box warning was included on this list. These four lists of drugs 
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with black box warnings corresponding to the four drug databases will be referred to as 
the databases’ “individual BBW lists”. (Figure 5) Of note, combination drugs, including 
those where one or multiple identifiable components were responsible for the black box 
warning, were included on the collective BBW list. 
In compiling this collective BBW list, it is important to note that disparities 
existed between the individual BBW lists with regards to which drugs contained a black 
box warning. Any drug listed as having a black box warning on at least one of the 
individual BBW lists was included on the collective BBW list.  This included drugs in 
which only certain dose(s) or route(s) possessed a corresponding BBW. In the case of 
DailyMed where multiple SPLs existed for particular drugs, some with a BBW, some 
without, only one SPL with a BBW was required to be included on the collective BBW 
list. (Figure 6)  
Drugs were listed alphabetically by generic name including combination drugs 
which were in addition alphabetized according to their component drugs. An effort was 
made to identify identical drugs listed in duplicate due to minor variations in the drugs’ 
names among the various drug databases. In these instances, the drug was listed under 
one name with the alternate name(s) in parentheses. For example, epoetin alfa and 
ethacrynate were listed with erythropoietin and ethacrynic acid in parentheses, 
respectively.  
From this collective BBW list, each drug specific BBW was analyzed.  As a 
federally funded and sponsored website with manufacturer package inserts uploaded 
electronically, DailyMed was used as the primary resource from which BBW information 
was extracted. When discrepancies existed between the BBWs from the various 
 15
databases, the BBW from DailyMed was used to create the table. (Figures 7&8) If a drug 
on the collective BBW list did not contain a BBW in DailyMed, then the BBW found in 
Micromedex was used. (Figure 9) When neither DailyMed nor Micromedex contained 
BBW information on a drug, the warning found in Facts & Comparisons was utilized. 
(Figure 10) BlackBoxRx’s BBW was used to create the table information when it was the 
sole resource for a drug BBW. (Figure 11) When BBW content discrepancies existed 
within a drug database for same formulation due to different dosing, routes, or SPLs from 
different manufacturers, the most complete or detailed BBW was used. (Figure 12) 
The BBW content gathered and analyzed in this fashion was used to create the 
“BBW table”. In order to maintain a succinct and manageable table, warnings were 
classified broadly by systems (e.g. torsade de pointe and myocardial infarction under 
cardiovascular; depression and suicidal thinking under psychiatric). Many cautionary 
statements contained in the black box warning did not pertain to the aforementioned 
classifications. These included cautions of drugs that should be reserved for or avoided in 
select patient populations, indications, or situations; had specific administration 
instructions; required or recommended monitoring of patients before/during/after use of 
the drug; alerted about concurrent medication/substance use; and/or forewarned of 
potential abuse and overdose. Examples of how various warnings within the BBWs were 
categorized on the BBW table can be seen in Table 1.  
Only warning information mentioned specifically within the BBW was included 
in the creation of the BBW table. When the BBW message referred the reader to other 
sections of the product label for additional warnings and instructions, this information 
was not analyzed nor included in the table. Also, any warning or cautionary symptoms 
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(e.g. rash, nausea, cough) mentioned in the BBW separately or as part of a clinical 
syndrome were presumed relevant and categorized on the BBW table. As an example, 
antipsychotics warn of “increased risk of death” and go on to specify that most were 
“either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in 
nature”. (Figure 13) Since “pneumonia” is listed as a specific example of cause of death, 
the “pulmonary” classification in addition to “cardiovascular” and “infectious diseases” 
are included for antipsychotics that carry this black box warning label. Symptoms 
typically associated with a system (e.g. “headache” with “neurologic”; “abdominal pain” 
with “gastrointestinal”) were categorized accordingly.   
When a risk was identified as pertaining distinctly to or being greater in a select 
population because of comorbid illness or concurrent medication, only the actual risk was 
classified on the table. In addition to this, the BBW categories for “Caution Select 
Circumstances” or “Concurrent Item Restriction” would be marked to indicate that a 
comorbid illness or concomitant medication, respectively, played a role in the BBW. For 
instance, metformin/repaglinide lists a warning for “lactic acidosis” and states that the 
“risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic 
impairment, renal impairment, and acute congestive heart failure.” (Figure 14) From this 
BBW statement, only the “Metabolic/Electrolyte Disturbance”, “Caution Select 
Circumstances”, and “Concurrent Item Restriction” categories were marked on the BBW 
table. 
The total number of BBWs with content pertaining to each classification on the 
table was also calculated. When multiple distinct warnings relevant to a common 
classification were found within a single BBW, that category was marked only once on 
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the BBW table and counted only once for the total number of classifications. For 
example, muronomab-CD3 contains a warning for “central nervous reactions” in addition 
to “seizures, coma, cerebral edema, cerebral herniation, … and paralysis.” (24) All of 
these warnings are classified under “neurologic” and counted as one “neurologic” BBW 
in the calculation. In addition, certain warning content could potentially belong to 
multiple classifications. As an example, methoxsalen warns of risk of “melanoma”. (25) 
Both the “dermatologic” and “oncologic” classifications were marked and counted 
towards the frequency of each category (one “dermatologic” BBW and one “oncologic” 
BBW) based on this risk. 
As mentioned previously, discrepancies existed between the drug databases; 
hence, the relative comprehensiveness of each was evaluated. This was achieved by 
identifying the presence or absence of a drug’s BBW in each database as compared to the 
collective BBW derived from all four resources as described above. Drugs not present on 
a database’s individual BBW list were searched for independently by generic and trade 
names using the database’s search function. Drug BBWs found in this manner were 
considered present even though not listed on the database’s individual BBW list. (Figure 
15) 
In some cases, the warnings were present as a BBW in one database but only as a 
bolded warningγ in others. These bolded warnings were identifiable in BlackBoxRx and 
DailyMed. When a warning was identified as a BBW in at least one database, it was not 
counted as present in the other databases that identified it as a bolded warning. The 
number of instances where this occurred was also calculated.  
                                               
γ Bolded warnings do not carry the same level of risk as BBWs. Similar to BBWs, they appear at the 
beginning of the package insert and are emphasized by bolded text but are not further accentuated with a 
black box. 
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BlackBoxRx’s individual BBW list did not include many combination drugs. 
When formerly listed under the name of Formweb, BlackBoxRx included a statement 
(since removed) notifying its users that combination drugs in which a separate black box 
warning was already listed under the responsible component drug(s) name(s) would not 
be included separately on its BBW list. Thus the omission of these combination drugs 
was considered intentional by BlackBoxRx. Any combination drug where its component 
drug(s) and BBW(s) were listed in BlackBoxRx and collectively contained the same 
warnings as found in the combination drugs was considered present for the purpose of 
determining the relative comprehensiveness of BlackBoxRx. In cases where the 
individual BBWs of components contained different information from the combination 
drug, the combination drug was considered missing from BlackBoxRx unless the 
combination drug was separately included on the individual BBW list. However, the 
other three drug databases did include combination drugs on their individual BBW lists 
even in cases where identifiable component drugs were responsible for the warning and 
were listed separately. Thus, combination drugs not listed on the other three resources 
were presumed to be unintentional and counted as missing even if their components were 
listed. The number of combination drugs counted as present in this manner was 
calculated for each database. 
Also, for all combination drugs on the collective BBW list, the responsible 
component(s) with a BBW were identified when possible. In some cases, the component 
drug would be explicitly mentioned in the BBW; otherwise, the combination drug 
warning was compared with the warning(s) of its component drugs to determine if it was 
the same for one or more of its constituents. In some instances the BBW pertained to that 
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specific combination drug and differed from its component drug warnings; in others, it 
was unclear which component(s) were responsible. These drugs were also identified. 
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Results: 
 A total of 635 drugs/drug combinations with black box warnings were 
collectively identified using the four aforementioned resources. (Table 2) Of these, 101 
were combination drugs. Combination drugs that carry BBW(s) identical to their 
component(s) are identified in the table by displaying the component drug(s) to which a 
BBW pertains in bold type. For example, the combination drug “abacavir 
sulfate/lamivudine/zidovudine” is presented on the table in all bolded font indicating that 
all three component drugs contribute to its BBW. For combination drugs where it is not 
discernible to which component(s) the BBW pertains, no part of the combination drug is 
bolded. This is seen a farther down the table with “acetaminophen/hydrocodone 
bitartrate”. 
The classifications for each drug’s black box warning are also displayed on Table 
2. It should be noted on the table that erlotinib hydrochloride is listed, but has no 
classification of its black box warning. This is due to the fact that while erlotinib 
hydrochloride is listed on the DailyMed individual BBW list, when referring to its SPL 
the BBW is an empty box. (Figure 16) (26) Also, Sodium Polystyrene Sulfonate shows 
no categorization in the table as its BBW simply states “cation-exchange resin”. (Figure 
17) (27) 
Table 3 depicts the frequency of BBWs on the collective BBW list that fall into 
each classification. The majority of warnings contained cautionary statements geared 
toward select patient populations or indications (66%) as well as administration and 
monitoring precautions (63%). Of organ systems, cardiovascular was the most affected 
with 200/635 (31%) BBWs, followed by pulmonary (144/635 or 23%), and 
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hematologic/bleeding (143/635 or 23%). Warnings pertaining to the eye (12/635 or 
1.9%), ears-nose-throat (ENT) (9/635 or 1.4%), endocrine system (8/635 or 1.3%), and 
autoimmunity (8/635 or 1.3%) were relatively infrequent. 
In order to determine the relative comprehensiveness of each drug resource, a 
comparison of the number of BBW drugs found in each of the four drug databases as 
compared to the collective BBW list is presented on Table 4. DailyMed contained the 
most drugs with a black box warning with 551/635. It was followed in succession by 
BlackBoxRx (536/635), Micromedex (514/635), and Facts & Comparisons (500/635). 
The number of combination drugs contributing to each database’s total is also presented 
on Table 4. The frequency of these combination drugs found in each database followed 
the same trend as the database’s total drugs. This last statement holds true provided that 
BlackBoxRx’s component drugs are added to its combination drug totals. As described in 
the methods, these 63 combination drugs, intentionally excluded from BlackBoxRx, had 
their component drug(s) that were responsible for the BBW listed in BlackBoxRx’s 
database.  
The number of BBW drugs found on the collective BBW list but missing from 
each individual drug database is tallied in the lower section of Table 4 along with the 
database’s method of exclusion. Three methods were identified: 1) The warning was 
present in the drug label as a bolded warning but was not listed as a black box warning. 
BlackBoxRx and DailyMed identified drugs with bolded warnings; BlackBoxRx listed 
seven drugs, DailyMed eight, that were listed as BBWs in at least one of the other 
databases. 2) The drug was listed in the database; however, it was not associated with a 
BBW. Despite specifically searching each database for drugs from the collective BBW 
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list, often these drugs were found not to contain a BBW in several of the databases. 3) 
The drug itself was not listed within the database. This last method was most frequent 
with BlackBoxRx as its database exclusively lists drugs with BBWs and bolded 
warnings. The only two listed for BlackBoxRx refer to “metoprolol tartrate” and 
“hydrochlorothiazide/metoprolol tartarte”. Metoprolol tartrate carries a more extensive 
BBW than metoprolol succinate. Metoprolol tartrate’s BBW contains additional 
precautions for patients with bronchospastic diseases, diabetes/hypoglycemia, 
pheochromocytoma, or undergoing major surgery. It also cautions of precipitation of 
thyroid storm with withdrawal of metoprolol tartrate in patients with thyrotoxicosis. (28) 
As BlackBoxRx lists only “metoprolol” in its database and the BBW does not include the 
extra precautions found in that for metoprolol tartarte, metoprolol tartrate and the 
combination drug hydrochlorothiazide/metoprolol are considered missing from the 
BlackBoxRx BBW list. 
Since no established gold standard resource for BBW drugs exists and omissions 
as well as add-ons existed within each database, the reliability of each was measured with 
respect to the others by looking at the consistency between the databases’ BBW lists. 
(Table 5) The four lists shared 416 BBW drug/drug combinations among all of them. 
BlackBoxRx maintained the highest consistency with the other databases, having both the 
most BBW drugs shared with two other databases (80/536) as well as with one (35/536). 
It also had the least number of BBW drugs where it was the sole source (5/536) and least 
number of BBW drugs missing from its list that were found on the other three lists (7/99). 
DailyMed had the most BBW drugs where it was the only resource listing them (55/551). 
Some examples of these “drugs” not found in the other three databases include 
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compounds such as allergy testing solutions (see boxelder maple pollen, cat hair/pelt, etc. 
on table), a “sterile water” preparation to be used “only with automated compounding 
devices”, and a drug (erlotinib hydrochloride) with an empty black box warning as 
mentioned above. (Figure 16) Facts & Comparisons had the second most number of 
BBW drugs only found in its database (17/500), four of which were listed only as bolded 
warning on two other lists. The actual package inserts of drugs such as these were not 




 No previous publication identifying and classifying all black box warnings was 
found through web searches or a literature review in PubMed. The BBW table developed 
for this thesis research constitutes the first record of any effort to classify and quantify 
data related to drug BBWs. The table provides an overview of which drugs the FDA 
designates as BBW compounds and categorizes their BBWs by affected systems relevant 
to their prescribing. As such, it can be used as an initial resource in identifying which 
drugs have serious adverse reactions requiring a BBW and what areas are of principle 
concern. It also serves as a valuable cue to recall specifics of black box warnings once 
these have been reviewed by the healthcare professional. 
 The types of precautions and concerns that the FDA deems an important element 
in these black box warnings have also been identified. As seen in Table 3, 416/635 BBW 
drugs (or 66%) contain information warning of increased risk associated with a specific 
patient population, indication, or clinical scenario. Many times the warning is relevant 
only to these circumstances. Nearly as frequent are specific instructions warning of routes 
of administration, experience/expertise required for prescribing, monitoring practices, 
and prerequisites for dispensing facilities (found in 402/635 BBW drugs). It should come 
as no surprise that the cardiovascular and pulmonary systems are the most frequently 
affected organ systems. 
These results also draw attention to the significant variability even among 
reputable resources in the drug information that is presented. The number of BBW drugs 
missing from each database ranged from 85 to 135. This constitutes a deficiency of 
between 13-21% when compared to the collective BBW list. The complete concurrence 
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in BBW lists between all four resources was only 65%. Ten percent of the drugs listed in 
DailyMed were not on any of the other three databases’ individual BBW lists. This brings 
into question the accuracy and efficiency with which black box warning information is 
conveyed. This is in addition to the questions that remain about the validity and utility of 
the black box warning itself: [1] How clinically relevant is the black box warning? [2] 
What is the best resource for accessing black box warning information? There has been 
much concern with regards to the first question which can be illustrated by the case of 
droperidol. (1) 
Droperidol 
Droperidol (Inapsine), is a member of the butyrophenone class of antipsychotic 
medications and was developed in the 1960’s by a Belgium company Janssen 
Pharmaceutica. Although used by psychiatrists and oncologists, in 1970 it received FDA 
approval as an injectable antiemetic and adjuvant to general anesthesia. (29) Despite the 
recommended starting dose of 2.5mg (IV) on the package insert, anesthesiologists as the 
drug’s chief prescribers would typically use a dose of 0.625mg to 1.25mg (IV) to achieve 
the desired effect. Over the next 30 years, these “off-label” low-dose regimens became a 
widely accepted first-line therapy for prophylaxis and treatment of post-operative nausea 
and vomiting (PONV) and by 2001 droperidol boasted roughly a 30% market share for 
antiemetics. (29,30,31,32,33) 
In the UK, droperidol was also available in an oral preparation (Droleptan) used at 
much higher doses in the chronic management of psychiatric patients. In the beginning of 
2001, the Medicines Control Agency (UK’s equivalent of the FDA) raised concerns 
regarding evidence of QT prolongation in psychiatric patients on chronic oral doses (>25 
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mg) of droperidol. (34,35) The proprietary maker of droperidol, Janssen-Cilag Ltd., 
decided to voluntarily withdraw all preparations from the UK market citing inadequate 
pricing and volume to justify the continued production of solely the parenteral 
formulation of droperidol used for PONV. (29,34,36)  
Still marketed in the U.S., the parenteral formulation of droperidol in turn that 
year received a BBW based on a review of 273 case reports the FDA had gathered over 
the preceding 4 years. (37,38) An Advisory Committee for the FDA had concluded from 
these case reports that there was enough evidence and concern for QT prolongation 
and/or torsades de pointes, in some cases resulting in death, that a BBW was warranted. 
The warning not only underscores these concerns but also extends the recommendation 
that droperidol be “reserved for use in the treatment of patients who fail to show an 
acceptable response to other adequate treatments” and stipulates that “ECG monitoring 
should be performed prior to treatment and continued for 2-3h after completing 
treatment”. (39) This action by the FDA created a commotion within the anesthesia 
community and many cried foul as to the merit and reasons behind their decision. (37,40)  
Of the 273 case reports, 127 were considered “serious adverse outcomes”, 74% of 
which were reports that came from outside the U.S. (37) Seventy-four of the 127 had 
evidence of a cardiac component, but only 17 (12 according to White PF (29)) of these 
occurred at doses ≤2.5 mg, 10 of which were ≤1.25 mg, the doses typically used for 
PONV. (37,40) A total of 89 deaths were reported, only 2 of which were in patients who 
received ≤2.5 mg, while the majority had received much larger doses (25-250 mg) that 
were typically used in psychiatric patients as mentioned previously. (37) Dr.’s Habib and 
Gan examined more closely the 10 cases involving doses of droperidol ≤1.25 mg and 
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found that none had demonstrated a cause-and-effect relationship, as many were subject 
to confounding factors including co-administration of other medications with known 
proarrhythmic effects. (40) 
Droperidol’s manufacturers were almost immediately affected by the FDA’s 
introduction of a BBW. In the year that followed, droperidol sales fell 10-fold and it 
disappeared off of many hospital formularies. (29,41) By 2007, a survey of 
approximately 300 anesthesiologists showed that use of droperidol as a first-line agent for 
both prophylaxis and treatment of PONV decreased from 47% & 38% to 5% & 8% 
respectively. (38) Of those not using droperidol, 39% cited so because of “medicolegal 
reasons” surrounding the BBW, 30% due to its nonavailablility; only 1.5% did so 
because they believed droperidol to be dangerous.  In the same survey, 92% also 
responded that they did not feel the BBW was justified and 60% stated that they would 
use droperidol as their first line agent for PONV prophylaxis if the BBW was removed. 
(38)  
The resulting increase in the use of other drugs such as promethazine, actually 
resulted in a concomitant increase in overall adverse events. (42,43) The 5-HT3 
antagonists (ondansetron, dolasetron, granisetron) that largely filled the gap in managing 
PONV left by droperidol’s spectacular decline had their own set of unique and not so 
unique problems. When the BBW was issued, generic droperidol was substantially less 
expensive: approximately 1/10 to 1/30 the cost of its replacement 5-HT3 antagonists 
(ondansetron, dolasetron, granisetron). (29) Ironically, the 5-HT3 antagonists too are 
associated with QTc prolongation and cardiac arrhythmias, resulting in Health Canada 
(the Canadian equivalent of the FDA) issuing a BBW for dolasetron. (41) Even in a study 
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done by its own manufacturer, ondansetron did not demonstrate any safety or efficacy 
advantages over low-dose droperidol. (29) Studies have even been performed to 
investigate another well-known butyrophenone, haloperidol, as a treatment for PONV as 
it does not contain a BBW for torsades de pointes and thus does not carry the same 
“medicolegal” repercussions or burdensome monitoring. (41,43)  
A number of studies involving droperidol at these lower doses have failed to 
demonstrate any cardiovascular adverse events such as arrhythmias, including torsades de 
pointes, or sudden death. (41,31,44,45) While it is true that even low-dose droperidol 
exhibits dose-dependent QTc prolongation, it is modest and short-lived. (41) 
Despite the mounting evidence as to the safety of low-dose droperidol for PONV, 
the BBW inclusion of “doses at or below recommended doses” persists. (39) During the 
2003 Advisory Committee meeting, the FDA medical office that spearheaded the BBW 
labeling for droperidol clarified that the BBW does not pertain to doses <2.5 mg, as these 
doses are off-label and lack sufficient evidence to linking them with a significant risk of 
QT prolongation and torsases de pointes. (43) It further emphasized that “clinicians 
should exercise medical judgements and use drugs according to their own medical 
judgment, [the FDA] really [doesn’t] regulate off-label use of drugs.” (43) This 
clarification has not changed how many health care providers and agencies view 
droperidol’s use. (43) The FDA did request that the then generic manufacturer Akorn 
Pharmaceuticals, perform a study or literature review to establish droperidol’s safety at 
these lower doses in order to receive separate labeling; however, Akorn declined, stating 
that this would not be economically feasible. (41,43) Even while advocating droperidol’s 
BBW, Ludwin et al. suggest that it needs to be modified to more appropriately state 
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“Doses of Inapsine below 2.5 mg are considered off-label. The FDA has no position on 
the safety or efficacy of doses below 2.5 mg.” (43) 
It is appropriate that the FDA has brought attention to the adverse cardiac events 
that can occur with the use of droperidol and that it continue to raise awareness for 
adverse reactions from other drugs as they percolate in via MedWatch, the new Sentinel 
system, and other post-marketing surveillance systems; however, care must be taken that 
the FDA issue its highest warning only when the situation warrants it, or risk indifference 
and inertia on the part of healthcare providers. 
Resources for Black Box Warning Information:    
DailyMed, as the federally funded repository for all mandated electronic drug 
labeling, was the most highly scrutinized and held to the highest standard.  It is a website 
run by the National Library of Medicine (NLM) that provides “a standard, 
comprehensive, up-to-date, look-up and download resource of medication content and 
labeling as found in medication package inserts” and “high quality information about 
marketed drugs”. (15) Despite these statements, on the very same introductory webpage 
DailyMed acknowledges “[DailyMed] does not contain a complete listing of labels for 
approved prescription drugs” and that “the drug labeling has been reformatted to make it 
easier to read but its content has not been altered or verified by FDA or National Library 
of Medicine”. (italics added)   
DailyMed did provide the most BBW drugs out of the four resources; however, 
10% of these were not found in any of the other resources and it was still missing 13% of 
the drugs found on the collective BBW list. DailyMed also appeared to provide the most 
detailed and accurate drug information as each individual drug package insert could be 
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viewed in its entirety. DailyMed also provides a “Drug Label Sections” menu at the 
beginning of the package insert that links to the various sections of the product label. 
(Figure 1) Drugs can be searched for individually by generic and/or trade names. Also as 
a free website it is readily available to any interested party. However, in practice its use is 
much more cumbersome than the other resources and despite boasting the most complete 
database in terms of the number of BBW drugs, finding accurate drug labeling was not 
always possible as will be illustrated. 
As DailyMed does not provide a distinct list of BBW drugs, the user is forced to 
search for each drug individually unless he/she possesses the technological savvy to 
extract this information from the downloadable XML files. Even if this is accomplished, 
navigating through the list is not so simple as many drugs are not listed once, but 
numerous times accounted for by each separate SPL for each manufacturer and 
formulation. Still more concerning, the content of these SPLs do not always provide the 
same information. This is best illustrated by looking at metformin hydrochloride as an 
example. 
A search for “metformin” using DailyMed yields 63 results. (Figure 18) Forty-
five of these are various formulations of metformin hydrochloride (tablet; tablet, film 
coated; tablet, extended release; etc.) while eighteen are combination drugs containing 
metformin. The vast majority contain the BBW seen in Figure 19. However, of the forty-
five individual metformin SPLs, five did not contain a BBW and one contained a highly 
inadequate BBW. (Figure 20 & Figure 21) Even among the 18 metformin combination 
drugs, five had abridged BBWs, three had no BBW, and one had a BBW pertaining to the 
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other constituent drug but not metformin (Figure 22). This supports the notion that the 
content found in DailyMed indeed needs to be verified by the FDA and NLM. 
Micromedex has the third most BBW drugs listed and was the second most 
consistent between the various databases. Micromedexθ is a private, fee-based, drug 
resource used in many hospitals, pharmacies, and clinics. It gives access to and pools 
from the drug information found in the Physicians’ Desk Reference (PDR) and Drugdexθ 
among other sources. Drug information, including black box warnings, are presented in 
drug “summary documents” which primarily draw upon Drugdex and link to this source 
when additional information is desired. Unlike DailyMed, Micromedex provides a 
distinct list of all drugs within its database that contain a BBW (Figure 5) When a drug is 
accessed from this BBW list, the user is taken to the black box warning section of the 
drug summary document. (Figure 2) The black box warning information in this section 
contains the same language as the official drug product labeling albeit at times abridged. 
It also clearly states the routes to which the BBW pertains and differences in the BBW 
for these if they exist. Similar to the “Drug Label Sections” menu in DailyMed, 
Micromedex contains a table of contents at the left hand margin which links the user to 
the various sections of the drug prescribing information. Above the summary document’s 
black box warning section is a link titled “(see details in DRUGDEX®)” which takes the 
user to the full BBW label as found in DailyMed. (Figures 1&2) The BBWs found in the 
“summary document” page as well as the Drugdex link were the primary source for BBW 
information gathered from Micromedex. Similar to DailyMed, it also has a search 
function which includes the ability to look for drugs by trade names and contains full 
                                               
θ Micromedex as well as Drugdex are products offered by Thomson Reuters Healthcare Division. 
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drug labeling information in addition to the BBW. However, unlike DailyMed, it requires 
a paid subscription for access. 
Facts & Comparisons was another drug resource utilized and is a subsidiary of 
Wolters Kluwer Health. Similar to Micromedex, it too provides a distinct BBW list. As 
compared to DailyMed and the Drugdex section of Micromedex, it does not usually 
include the exact wording of a BBW but in most cases a truncated rearrangement with 
pertinent details (Figures 3 & 5). Unlike the other two, however, it does allow BBW 
searches by therapeutic classes and includes these therapeutic classes on its BBW list. A 
unique feature of Facts & Comparisons when compared to the other three is its search 
function which has an auto fill feature to help the user with his/her query. (Figure 23) 
Of the four resources, Facts & Comparisons had the least number of drugs on its 
individual BBW list. This is despite the fact that 29 of the drugs included were not 
actually on their BBW list (Figures 5 & 19) but were found to have a BBW by using its 
search function to individually look for BBW drugs that were found on other lists. 
(Figure 15) It also had at least four instances where it likely listed a black box warning 
inappropriately for drugs containing a bolded warning. It, too, requires a paid 
subscription. 
BlackBoxRx.com, as the name implies, is a web-based list of only those 
medications that carry a black box warningψ. It is published and updated by Dr. Joyce 
Generali, Director of the Drug Information Center at the University of Kansas Hospital. 
BlackBoxRx provides an alphabetized list of BBW drugs by generic drug name. (Figure 
5) Similar to Facts & Comparisons, drugs can also be searched for by therapeutic class. 
                                               
ψ BlackBoxRx also lists drugs with a bolded warning connoted by a “*” next to the name. 
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The black box warnings typically contain key information in the same language as used 
in the actual product labels (SPLs in DailyMed) though in bullet format and often 
truncated to remove seemingly repetitive information. (Figure 24) Information on when 
the BBW was last updated is clearly displayed and the user is able to sign up for email 
notification of any future updates.  
BlackBoxRx had the second most BBW drugs listed as well as the greatest degree 
of concordance with the other databases. However, unlike the other three, it does fail to 
provide an individual drug search function including the ability to search for drugs by 
trade name, does not include drug label information in addition to the BBW nor a web 
link to this, and does not disclose what resources were utilized to compile its BBW list. 
BlackBoxRx also does not specifically include many combination drugs and does not list 
many specific formulations (e.g. metoporolol tartrate and metoprolol succinate) though 
often in these latter cases it will identify the route of administration which is often 
formulation specific (e.g. it does not list olanzapine and olanzapine palmoate separately 
but does list olanzapine “oral and injectable formulations”). The best features of this 
website arguably are its concise presentation and free access, providing useful 
information to clinicians and patients alike. 
Limitations 
There are a number of limitations with the data presented in this paper. Only four 
of the numerous resources for black box warnings available to the practitioner or patient 
were utilized in identifying drugs that contained a BBW. Doing so may not have 
accounted for all the drugs that contain a BBW and resulted in an incomplete table.  
Likewise, it is also possible that some of the drugs presently included in the BBW table 
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may have erroneously been included as the actual package inserts were not examined to 
confirm. Also, drugs were included on the list even if the BBW was found in only one of 
the resources and/or if the BBW pertained only to one or several of many specific 
preparation(s), dose(s), or route(s), making each drug inclusion only as reliable as the 
source where it was listed. No distinction was made in the table with regards to which 
database was utilized for which drug or which dose(s) or route(s) carry the black box 
warning.  
In addition, the BBW information analyzed in order to categorize each warning 
was taken only from one resource as described in the methods. Many times it was found 
to not contain the exact same BBW information present in other databases. In comparing 
each database to the others, it was only verified that a BBW was present/absent for each 
drug, not that the information was identical. 
An attempt was made to include all content from the black box warning in the 
table, even if the included symptom or event was not perceived to be “life threatening or 
permanently disabling” itself, per se. A BBW that specifically included “nausea” would 
receive a gastrointestinal categorization on the table and be indistinguishable from a drug 
that warned of “ischemic colitis” by looking at the table. Thus, classifications marked on 
the table do not always reflect on what may be perceived as the primary reason for the 
BBW, but highlight what systems/symptoms are affected and thus what areas deserve 
special attention.  
The categories were selected by the author to best describe in a concise and 
displayable manner the exceptionally varied BBWs, and only gives the reader a general 
idea of affected organ systems or other general precautions included in the BBW. They 
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fail to give the complete details of each BBW as well as other pertinent information 
including other adverse effects, contraindications, precautions, prescribing information, 
and precautionary actions to be taken for these as described both inside the BBW and 
elsewhere in the package labeling.  
Also, the information contained in this paper is only as current as when the data 
were evaluated and does not reflect any additional changes made to current drugs nor to 
drugs that have since been added or removed. The author attempted to describe as 
specifically as possible the manner in which the BBW table and other results were 
derived to allow the reader the ability to determine how best to use this information for 
himself/herself. 
Conclusion: 
While the FDA has already taken great strides towards fulfilling the initiatives set 
forth in the Food and Drug Administration Amendments Act of 2007, a great deal of 
ground has yet to be covered. (46) For health care providers’ confidence to be restored 
and maintained in the black box warning system, such warnings need to be founded on 
sound clinical evidence with clear and timely distribution to the practitioner. A more 
focused and organized BBW could help with physician and patient adherence. Many of 
the black box warnings contain a redundancy of precautions that would be more forceful 
if stated concisely. BBWs that explicitly state the contraindications or cautionary actions 
to be taken do have better physician compliance than those that do not. (10) As the 
organization of the package insert has become more clearly defined, so should the black 
box warning itself with a succinct statement of risks, the population or circumstance to 
which these risks apply, and what actions should be taken; this before a more detailed 
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explanation of risks and reference to supporting evidence is made. Supporting evidence is 
critical to ensure that the same mistakes are not made as were seen with droperidol. 
Referring to paucity of proof used in their decision to place the black box warning, Dr. 
Chang, the FDA medical officer in charge of droperidol labeling, stated, “Unfortunately, 
this is not atypical. We see a lot of cases like this where the information is just simply 
incomplete.” (43) Dr. Chang’s comments not only highlight this regrettable reality but 
also the need to effect its change. 
The FDA’s most stern warning is only as effective as the medium in which it is 
communicated. Inconsistencies seen with the black box warnings raise questions as to the 
accuracy of other product label information being presented to the healthcare community 
and public at large. As “America’s consumer watchdog for medicines” and sole 
sovereign over the issuance and content of BBWs, the FDA is in the best position to act 
as the preeminent resource for black box warning information. Whether or not they elect 
to do so remains to be seen. 
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Tables and Figures: 
 
 
Figure 1: Capecitabine as example black box warning from DailyMed.  
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Figure 2: Capecitabine as example black box warning from Micromedex. Red box highlights black 
box warning link in side bar table of contents that takes the user to the black box warning section of 
the drug’s “summary document”.  Further information is available by clicking on the Drugdex link 
(thick green box) which takes the user to the black box warning section of Drugdex (thin green box).  
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Figure 3: Capecitabine as example black box warning from Facts & Comparisons.  
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Figure 4: Capecitabine as example black box warning from BlackBoxRx.  
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 Figure 5: From left to right, screenshots of sections from the individual BBW lists for 
BlackBoxRx, Micromedex, Facts & Comparisons, and DailyMed. 
 42
 
Figure 6: Screenshots of sections from two of the SPLs found in Daily Med for naproxen. The red 
boxes highlight the tab indicating the presence/absence of a BBW with each. Note that the SPL for 




Figure 7: Example of DailyMed as the source for BBW content. DailyMed BBW for a specific 
formulation of bupropion hydrochloride is shown. (Compare to Facts & Comparisons BBW for 
bupropion in Figure 8) 
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Figure 8: Facts & Comparisons black box warning for bupropion hydrochloride. Note that in this 
instance, when compared to the DailyMed BBW this warning provides less information. 
Figure 9: Example of Micromedex as the source for BBW content. Top: Screenshot of SPL excerpt 
for deferasirox showing no BBW (red box). Below: Micromedex BBW for deferasirox. 
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Figure 10: Example of Facts & Comparisons as source for BBW content. Top: DailyMed 
screenshot of SPL excerpt for Flunisolide showing no BBW. Middle: Micromedex screenshot also 
showing no BBW. Bottom: Facts & Comparisons BBW for Flunisolide. 
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Figure 11: Example of BlackBoxRx as source for BBW content. Top: DailyMed screenshot of 
search for pimozide yielding no results. Second to top: Micromedex screenshot showing no BBW; 
smaller box with blue outline showing “pimozide” not on individual BBW list. Second to bottom: 
Facts & Comparisons showing no BBW; smaller box outlined in blue showing “pimozide” not on 
individual BBW list. Bottom: BlackBoxRx BBW for pimozide with smaller box outlined in blue 





Figure 12: Nadolol as an example of BBW discrepancies within drug databases due to dosing, 
routes, and/or differing SPLs for different manufacturers. In DailyMed, above left shows BBW for 
nadolol USP which carries a more extensive BBW. Above right shows BBW for remaining four 
preparations of Nadolol listed on DailyMed. 
 48
Table 1: Warning Classification Examples
Effects on Organ Systems Examples from Select Black Box Warnings
Cardiovascular
hypotension, syncope, arrhythmias, heart block, heart failure, sudden death, cardiovascular adverse events, 
cardiac arrest, cardiopulmonary arrest, exacerbation angina, myocardial infarction, hypertension, myocarditis, 
Pulmonary
respiratory symptoms, dyspnea, pulmonary embolism, pulmonary toxicity, hypersensitivity pneumonitis, 
interstitial/alveolar pneumonitis, respiratory arrest, pneumonia, respiratory depression, hypoxia, resp paralysis
Hematologic/Bleeding
bone marrow suppression, leukopenia, anemia, thrombocytopenia, cytopenias, hemorrhagic diathesis, 
hemolytic/aplastic anemia, agranulocytosis, other blood dyscrasias, myelosuppression, DVT, lymphoma
Neurologic
dementia, headache, chemical arachnoiditis, seizures, stroke, CNS adverse events, confusion, neuropsychiatric 
events/disorders, ototoxicity, encephalitis, CNS-additive effects, neurotoxicity, quadraparesis,
Infectious Disease
hepatitis B exacerbation, increase susceptibility to infection, pneumonia, encephalitis, sepsis, disseminated 
infection,  bacterial endocarditis, intra-abdominal abscess, progressive multifocal leukoencephalopathy
Teratogenicity/Fetal Harm
adversely affected fetal circulation, teratogenicity, birth defects, fetal death, major human fetal abnormalities, 
embryotoxic,  injury and death to the developing fetus, neural tube defects, spina bifida, 
Gastrointestinal
nausea, vomiting, diarrhea, abdominal pain, gastrointestinal bleeding/ulceration/perforation, peptic ulcers, 
dysphagia, pancreatitis, ischemic colitis, gastrointestinal adverse events, complications from constipation
Psychiatric
dementia, confusion, depression, neuropsychiatric events/disorders, suicidal thinking and behavior (suicidality), 
psychotic episodes, affect changes, 
Oncologic
development of neoplasia, lymphoma, skin malignancies, breast cancer, mutagenic, tumorigenic, carcinogenic, 
thyroid C-cell tumor, endometrial cancer, 
Hepatic
hepatomegaly with steatosis, liver injury, overt liver disease, hepatic/liver dysfunction/failure, hepatitis B 
exacerbation, hepatotoxicity, fulminant hepatic necrosis, elevation of liver aminotransferases, cirrhosis, 
Hypersensitivity and Other Rxns
hypersensitivity reactions, systemic allergic reaction, anaphylaxis, bronchospasm, sensitization, infusion 
reactions, severe systemic reactions, hypersensitivity pneumonitis, severe idiosyncratic reaction, 
Dermatologic/Soft Tissues
rash, skin malignancies, cutaneous/mucocutaneous reactions, erythema multiforme, Stevens-Johnson 
syndrome, toxic epidermal necrolysis, severe tissue damage, oral ulceration, flushing, local tissue necrosis,
Renal
nephrotoxicity, renal insufficiency/impairment/injury, renal toxicity, nephropathy, acute renal failure, 
profound/osmotic diuresis, 
Metabolic/Electrolyte Disturbance
lactic acidosis, electrolyte disturbances, hyperkalemia, metabolic acidosis/alkalosis, hypophospatemia, 
hypocalcemia, hyperosmolar non-ketotic states, dehydration, alterations in plasma minerals and electrolytes
Musculoskeletal
generalized muscle weakness, loss of bone mineral density, rhabdomyolysis, muscle rigidity, tendinitis, tendon 
rupture, contracture of arms, back pain,  system fibrosis affecting muscle, skeletal muscle myopathy, 
Genitourinary
urinary incontinence, testicular lesions, urinary tract obstruction, decreased fertility, hypospermia, endometrial 
cancer, uterine rupture, abnormal vaginal bleeding, aspermatogenesis, urotoxic side effects, hemorrhagic 
Ophthalmic
diplopia, blurred vision, blindness, loss of visual accuity and color vision, lacrimation, occular damage, optic 
nerve dysfunction, 
ENT (ears/nose/throat)
ototoxicity, deafness, hearing loss, cranial nerve VIII impairment, tinnitis, loss of high-frequency hearing, rhinitis,  
roaring in ears, 
Endocrine  reduced the release of insulin, thyrotoxicosis, adrenal suppression, thyroid storm, thyroid C-cell tumor,
Autoimmune
autoimmune disorders, autoimmune idiopathic thrombocytopenia, autoimmune hemolytic anemia, lupus 
erythematosus-like syndrome, 
Other Effects Examples from Select Black Box Warnings
Caution Select Circumstances 
A should not be used for/to treat [ ], Patients with [ ] advised against, caution used in patients having a history of [ 
], not approved for the treatment of patients with [ ], increased risk of [ ] in [ ] patients, contraindicated in [ ]
Admin/Monitoring Instructions 
B hospitalization required during administration, patient should be carefully observed, only physicians experienced 
in [ ] should prescribe, [drug A] and [drug B] are not bioequivalent, [labs] should be monitored, caution used 
Concurrent Item Restriction 
C avoid use of [ ] in combination with [ ], caution when [treatment] initiated in patients taking [ ], the concomitant 
use of [ ] with [ ] may result in [ ], not be used with [ ], risk increased in patients taking [ ], in state of EtOH 
Reserve for Select Circumstances 
D intended for/reserved for use only in patients with [disease/diagnosis], should be used primarily for treatment of 
patients with [ ], indicated for [ ], should be considered only for [ ], should restricted to patients with [ ]
Abuse Potential
high potential for abuse, abuse potential, do not prescribe for patients who are addiction-prone, known to cause 
dependence or abuse, psychological/drug dependence, 
Overdose/Poisoning exercise caution to prevent inadvertent overdose, overdose, resulting dose may be fatal, 
A
 Caution or avoidance with select patient populations,indications, or clinical situations
B 
Administration or monitoring instructions
C 
Caution or avoidance of select concurrent medications, treatments, or substance use
D 
Use reserved for select patient populations, indications, or clinical situations
"[ ]" is intended to signify various mention comorbidities, risks, indications, and concurrent medications among the black box warnings.
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Figure 13:Asenapine as an example of antipsychotics’ BBW which cautions of “increased risk of 
death”.  In highlighted section, example causes of “heart failure”, “sudden death”, and 
“pneumonia” are given and as such are included on the BBW table. 
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Figure 14: Metformin/Repaglinide BBW from DailMed. “Lactic acidosis” highlighted in green is 
classified on the BBW table under “Metabolic/Electrolyte Disturbance”. Blue highlight indicates 
comorbid conditions/illnesses that increase risk of lactic acidosis but are not themselves a result 
of metformin/repaglinide use. These are classified under “Caution Select Circumstances” 
Increased risk of lactic acidosis secondary to “excess alcohol intake” highlighted in pink is 
classified under “Concurrent Item Restriction”. 
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Figure 15: Daclizumab as an example of a drug not found on a database’s individual BBW list, 
however, with further searching is discovered to have a BBW mentioned n that database. In this 
example, Facts & Comparisons does not list daclizumab on its individual BBW list (above); 
however, doing an individual search for daclizumab in Facts & Comparisons indeed shows that it 
does have a BBW in this database (below). Thus when calculating the relative comprehensiveness 
of the drug databases, this BBW was counted as present for Facts & Comparisons. 
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Table 2: Compiled Black Box Warning Table
Drugs (Generic Name):
Abacavir Sulfate ● ● ● ● ● ● ● ● ●
Abacavir Sulfate/Lamivudine ● ● ● ● ● ● ● ● ● ● ●
Abacavir Sulfate/Lamivudine/Zidovudine ● ● ● ● ● ● ● ● ● ● ● ●
Abarelix ● ● ● ●
AbobotulinumtoxinA (botulinum toxin type a) ● ● ● ● ● ● ●
Acetaminophen/Hydrocodone Bitartrate ● ● ● ●
● ● ● ● ● ● ●
Acetaminophen/Propoxyphene Napsylate ● ● ● ● ● ● ●
Acetazolamide ● ● ● ● ● ●
Acetylcysteine Inhalant ●
Acitretin ● ● ● ● ●
Adalimumab ● ● ●
Adefovir Dipivoxil ● ● ● ● ●
Albuterol ● ●
Aldesleukin ● ● ● ● ● ● ● ● ● ●
Alemtuzumab ● ● ● ● ●




Allergenic Extract (Box Elder Maple Pollen) ● ●
● ● ●
● ● ●
Alosetron Hydrochloride ● ● ● ●
Alprostadil ● ● ●
Altretamine ● ●
Alvimopan ● ●
Ambrisentan ● ● ● ● ● ●
Amikacin Sulfate ● ● ● ● ● ● ●
Amiloride Hydrochloride ● ● ●
● ● ●
Amino Acids (Novamine) ●
Aminosyn ● ● ● ● ● ● ● ● ●
Amiodarone Hydrochloride ● ● ● ● ● ● ● ●
Amitriptyline Hydrochloride ● ● ●
● ● ●
Amitriptyline/Perphenazine ● ● ● ● ● ●
● ●




Amoxapine ● ● ●
Amphetamine ● ● ●
Amphetamine/Dextroamphetamine ● ● ●
Amphotericin B ● ● ● ● ● ●
Ampicillin/Sulbactam ●
Amprenavir ● ● ●
Antithymocyte Globulin Equine ●
●
● ●
Aprotinin ● ● ● ●
Arformoterol Tartrate ●
Aripiprazole ● ● ● ● ● ●
Armodafinil ●
Arsenic Trioxide ● ● ● ● ● ●
Asenapine ● ● ● ●
Asparaginase ● ●
Atenolol ● ● ●
Atomoxetine Hydrochloride ● ● ● ●
Auranofin ● ● ● ● ● ●
Azathioprine ● ●
























































































































































































































































Allergenic Extracts for Scratch, Prick, or 
Puncture Testing(pollens etc.)








Antithymocyte Globulin Rabbit 
(Thymoglobulin)
Antivenin (Crotalidae) Polyvalent (Equine 
Origin) 








































































































Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































Bacitracin ● ● ● ●
Baclofen Intrathecal ● ● ● ●
Bacteriostatic Water ●
Basiliximab ●
Becaplermin (Topical) ● ● ●
Benazepril Hydrochloride ● ●
Benazepril/Hydrochlorothiazide ● ●
Bendroflumethiazide/Nadolol ● ● ● ● ●
Bermuda Grass, Standardized ● ● ● ● ● ●




Bleomycin Sulfate ● ● ● ● ●
Bosentan ● ● ● ● ● ●
Budesonide Inhalation ● ●
Budesonide/Formoterol ● ●
Bumetanide ● ● ●
Bupivicaine (0.75% inj) ● ● ● ●
Bupropoin Hydrobromide ● ● ●
Bupropion Hydrochloride ● ● ● ●
Busulfan ● ●
Butorphanol Tartrate ● ● ●
Caffeine/Ergotamine Tartrate ● ● ●
Candesartan Cilexetil ● ●
Candesartan Cilexetil/Hydrochlorothiazide ● ●
Capecitabine ● ● ● ●
Capreomycin ● ● ● ● ●
Captopril ● ●
Captopril/Hydrochlorothiazide ● ●
Carbamazepine ● ● ● ●
Carbonyl Iron ● ●
Carboplatin ● ● ● ● ●
Carboprost ●
Carmustine Implant ● ●
Carmustine Injection ● ● ● ● ●
Cat Hair ● ●
Cat Hair, Standardized ● ● ● ●
Cat Pelt, Standardized ● ● ● ● ● ●
Cefaclor ●
Cefadroxil Monohydrate ●
Celecoxib ● ● ● ● ●
Cephalexin ●
Certolizumab Pegol ● ● ● ●
Cetuximab ● ● ● ● ● ●
Chenodiol ● ● ● ● ●
Chlorambucil ● ● ● ●
Chloramphenicol ● ● ● ●
Chloroquine Phosphate ● ●
Chlorpromazine Hydrochloride ● ● ● ●
Cidofovir ● ● ● ● ● ● ● ●
Cilostazol ●
Ciprofloxacin ● ● ●
Ciprofloxacin Hydrochloride ● ● ●
Cisapride ● ● ● ●
Cisplatin ● ● ● ● ● ● ● ● ● ●
Citalopram Hydrobromide ● ● ●
Cladribine ● ● ● ● ●
Clarithromycin ●
Clindamycin Hydrochloride ● ● ●
Clindamycin Palmitate Hydrochloride ● ● ●
Clindamycin Phosphate ● ● ●
Clomipramine Hydrochloride ● ● ●
Clonidine Hydrochloride Epidural ● ● ●
Clopidogrel Hydrogen Sulfate ● ● ●
Clozapine ● ● ● ● ● ● ● ●










Table 2: Compiled Black Box Warning Table (continued)











































































































































































































































































































































































Colistimethate Sodium ● ● ●
Conjugated Estrogens ● ● ● ● ● ● ● ●
Conjugated Estrogens Synthetic A ● ● ● ● ● ● ● ●
Conjugated Estrogens Synthetic B ● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
Cyclosporine ● ● ● ● ● ●
Cyclosporine, Modified ● ● ● ● ● ● ● ●
Cysteine Hydrochloride ●
Cytarabine ● ● ● ● ●
Cytarabine Liposome ● ● ●
Dacarbazine ● ● ● ● ●
Daclizumab ●
Dactinomycin ● ● ● ● ● ●
Dalfopristin/Quinupristin ●
Dalteparin Sodium ● ● ● ●
Danazol ● ● ● ● ● ● ● ● ●
Dantrolene Sodium ● ● ● ●
Darbepoetin Alfa ● ● ● ● ● ●
Daunorubicin Citrate Liposome ● ● ● ● ● ●
Daunorubicin Hydrochloride ● ● ● ● ● ●
Deferasirox ● ● ● ● ● ●
Delavirdine ●
Denileukin Diftitox ● ● ● ●
Deserpidine/Methylclothiazide ● ●
Desipramine Hydrochloride ● ● ●
Desirudin ● ● ● ●
Desmopressin ●
Desogestrel/Ethinyl Estradiol ● ● ●
Desvenlafaxine Succinate ● ● ●
Dexibuprofen ● ● ● ● ●
Dexmethylphenidate Hydrochloride ● ● ● ●
Dextroamphetamine Sulfate ● ●




Diatrizoate Meglumine/Diatrizoate Sodium ●
Diclofenac Epolamine ● ● ● ● ●
Diclofenac Potassium ● ● ● ● ●
Diclofenac Sodium ● ● ● ● ●
Diclofenac Sodium/Misoprostol ● ● ● ● ● ● ●
Didanosine ● ● ● ● ●
Diflunisal ● ● ● ● ●
Dihydroergotamine Mesylate ● ● ●
Dinoprostone ●
Disopyramide Phosphate ● ● ●
Disulfiram ●
Divalproex Sodium ● ● ● ● ● ● ● ●
Docetaxel ● ● ● ● ● ● ● ● ●
Dofetilide ● ●
Dopamine ● ● ●
Doxepin Hydrochloride ● ● ●
Doxorubicin Hydrochloride ● ● ● ● ● ● ●
Doxorubicin Hydrochloride Liposome ● ● ● ● ● ● ● ● ● ●
Dronedarone Hydrochloride ●
Droperidol ● ● ● ● ●
Drospirenone/Estradiol ● ● ● ● ● ● ● ●
Drospirenone/Ethinyl Estradiol ● ● ●
Duloxetine Hydrochloride ● ● ●
Ecallantide ● ● ●
Echothiophate Iodide ●
Eculizumab ● ●
Edetate Calcium Disodium ● ● ●
Edetate Disodium ●
Efalizumab ● ● ●
Efavirenz/Emtricitabine/Tenofovir ● ● ● ● ● ●
Eltrombopag Olamine ● ●








Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































● ● ● ● ● ●
Enalapril Maleate ● ●
Enalapril Maleate/Felodipine ● ●
Enalapril Maleate/Hydrochlorothiazide ● ●
Enalaprilat ● ●
Encainide Hydrochloride ● ● ●
Enoxaparin Sodium ● ● ● ●
Entecavir ● ● ● ● ● ●
Epirubicin Hydrochloride ● ● ● ● ● ● ●
Epoetin Alfa (Erythropoietin) ● ● ● ● ● ●
Eprosartan Mesylate ● ●
Eprosartan Mesylate/Hydrochlorothiazide ● ●
Ergotamine Tartrate ● ● ●
Erlotinib Hydrochloride BBW BOX IS EMPTY
Erythromycin Estolate ● ● ●
Escitalopram Oxalate ● ● ●
Esterified Estrogens ● ● ● ● ● ● ● ●
Esterified Estrogens/Methyltestosterone ● ● ● ● ● ● ● ● ●
Estradiol ● ● ● ● ● ● ● ● ●
Estradiol Acetate ● ● ● ● ● ● ● ● ●
Estradiol Cypionate ● ● ● ● ● ● ● ● ●
● ● ● ● ● ● ● ● ●
Estradiol Valerate ● ● ● ● ●
Estradiol/Levonorgestrel ● ● ● ● ● ● ● ●
Estradiol/Norethindrone Acetate ● ● ● ● ● ● ● ●
Estradiol/Norgestimate ● ● ● ● ● ● ● ●
Estropipate ● ● ● ● ●
Etanercept ● ● ●
Ethacrynate (Ethacrynic Acid) ● ● ● ●
Ethinyl Estradiol/Ethynodiol Diacetate ● ● ●
Ethinyl Estradiol/Etonogestrel ● ● ●
Ethinyl Estradiol/Levonorgestrel ● ● ●
Ethinyl Estradiol/Norelgestromin ● ● ●
Ethinyl Estradiol/Norethindrone ● ● ●
● ● ● ● ● ● ● ●
Ethinyl Estradiol/Norgestimate ● ● ●
Ethinyl Estradiol/Norgestrel ● ● ●
Etodolac ● ● ●
Etoposide ● ● ●
Etoposide Phosphate ● ● ●
Fat Emulsion (Liposyn) ● ● ●
Felbamate ● ● ● ● ● ● ● ●
Fenoprofen Calcium ● ● ● ● ●
Fentanyl (transdermal) ● ● ● ● ● ● ●
Fentanyl Citrate (buccal) ● ● ● ● ● ● ●
Fentanyl Iontophoretic Transdermal System ● ● ● ● ●
Ferrous Aspartate ● ●
Ferrous Fumarate ● ●
Flecainide Acetate ● ● ● ●
Floxuridine ●
Flucytosine ● ●
Fludarabine Phosphate ● ● ● ● ● ● ● ●
Flumazenil ● ● ● ●
Flunisolide ● ● ●
Fluorouracil ●
Fluoxetine Hydrochloride ● ● ●
Fluoxetine Hydrochloride/Olanzapine ● ● ● ● ● ●
Fluphenazine Decanoate ● ● ● ●
Fluphenazine Hydrochloride ● ● ● ●
Flurbiprofen ● ● ● ● ●
Flutamide ● ● ● ● ●
● ●
Fluvoxamine Maleate ● ● ●
Fomepizole ●
Fondaparinux Sodium ● ● ● ●
Formoterol Fumarate ● ●
Foscarnet Sodium ● ● ● ● ●
Fosinopril Sodium ● ●







Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































Fosinopril Sodium/Hydrochlorothiazide ● ●
Furosemide ● ● ● ●
Gadobenate Dimeglumine ● ● ● ●
Gadodiamide ● ● ● ●
Gadofosveset Trisodium ● ● ● ●
Gadopentetate Dimeglumine ● ● ● ●
Gadopentetic Acid ● ● ● ●
Gadoteridol ● ● ● ●
Gadoversetamide ● ● ● ●
Gadoxetate Disodium ● ● ● ●
Gallium Nitrate ● ● ● ●
Gamma Hydroxybutyrate ● ● ● ● ● ●
Ganciclovir (Oral) ● ● ● ● ●
Ganciclovir Sodium (IV) ● ● ● ● ●
Gemifloxacin Mesylate ● ● ●
Gemtuzumab Ozogamicin ● ● ● ● ● ● ● ● ●
Gentamicin Sulfate (Inj) ● ● ● ● ● ● ●
Glimepiride/Pioglitazone Hydrochloride ● ● ● ●
Glimepiride/Rosiglitazone Maleate ● ● ● ●
Glipizide/Metformin Hydrochloride ● ● ● ● ● ● ● ● ●
Glyburide/Metformin Hydrochloride ● ● ● ● ● ● ● ● ●
Gold Sodium Thiomalate ●
Golimumab ● ● ● ●
Haloperidol ● ● ● ●
Haloperidol Decanoate ● ● ● ●




Honey Bee Hymenoptera Venom Multidose ● ● ● ●
House Dust Mite, Dermatophagoides Farinae ● ● ●
Human Chorionic Gonadotropin ●
Human Immunoglobulin G ● ● ● ●




Hydrochlorothiazide/Losartan Potassium ● ●
Hydrochlorothiazide/Methyldopa ● ●
Hydrochlorothiazide/Metoprolol Succinate ● ● ●





Hydrochlorothiazide/Spironolactone ● ● ●
Hydrochlorothiazide/Telmisartan ● ●
Hydrochlorothiazide/Triamterene ● ● ●
Hydrochlorothiazide/Valsartan ● ●
Hydrocodone Bitartrate/Ibuprofen ● ● ● ● ●
●
Hydromorphone Hydrochloride ● ● ● ● ● ● ●
Hydroxychloroquine Sulfate ●
Hydroxyurea ● ● ● ●
Ibritumomab Tiuxetan ● ● ● ● ● ● ●
Ibuprofen ● ● ● ● ●
Ibuprofen/Oxycodone ● ● ● ● ●
Ibutilide Fumarate ● ● ●
Icodextrin ● ● ●
Idarubicin Hydrochloride ● ● ● ● ● ●
Idursulfase ● ● ● ●
Ifosfamide ● ● ● ●
Iloperidone ● ● ● ●
Imipramine Hydrochloride ● ● ●
Imipramine Pamoate ● ● ●
Immune Globulin ● ● ● ●
Indomethacin ● ● ● ● ●









Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































Interferon Alfa-2a ● ● ● ● ●
Interferon Alfa-2b ● ● ● ● ●
Interferon Alfacon-1 ● ● ● ● ●
Interferon/Ribavirin ● ●




Ioversol ● ● ● ● ● ● ● ● ● ●
Ioxaglate Meglumine/Ioxaglate Sodium ● ● ● ● ● ● ● ● ● ●
Irbesartan ● ●
Irinotecan Hydrochloride ● ● ● ● ● ● ● ● ● ●
Iron Dextran ● ● ●
Isocarboxazid ● ● ●
Isoniazid ● ● ● ● ● ● ●
Isoniazid/Pyrazinamide/Rifampin ● ● ● ● ● ● ●
Isoniazid/Rifampin ● ● ● ● ● ● ●
Isotretinoin ● ● ●
Itraconazole ● ● ●
Ixabepilone ● ● ●
Kanamycin ● ● ● ● ● ● ●
Ketoconazole ● ● ● ●
Ketoprofen ● ● ● ● ●
Ketorolac Tromethamine ● ● ● ● ● ● ● ● ● ●
Lamivudine ● ● ● ● ● ●
Lamivudine/Zidovudine ● ● ● ● ● ● ● ●
Lamotrigine ● ● ● ●
Lansoprazole/Naproxen ● ● ● ● ●
Lapatinib Ditosylate ●
Laronidase ● ● ● ●
Leflunomide ●
Lenalidomide ● ● ● ● ● ●
Levofloxacin ● ● ●
Levomethadyl ● ● ● ●
●
Levothyroxine Sodium ● ●
Lincomycin Hydrochloride ● ● ●
Lindane ● ● ● ●
Liothyronine Sodium ● ●
Liotrix ● ●
Liraglutide ● ●




Lithium Hydroxide Monohydrate ●
Lomustine ● ● ●
Losartan Potassium ● ●
Loxapine ● ● ● ●
Lymphocyte Immune Globulin ● ● ● ●
Maprotiline Hydrochloride ● ● ●
Maraviroc ● ● ● ●
Mechlorethamine Hydrochloride ● ● ● ● ●
Medroxyprogesterone Acetate ● ● ● ● ● ● ● ● ●
Mefenamic Acid ● ● ● ● ●
Meloxicam ● ● ● ● ●
Melphalan ● ● ● ●
Melphalan Hydrochloride ● ● ● ● ●
Mercaptopurine ● ●
Mesoridazine Besylate ● ●
Metformin Hydrochloride ● ● ● ● ● ● ● ● ●
● ● ● ●
● ● ● ● ● ● ●
● ● ● ● ● ● ● ●
● ● ● ● ● ● ●
Methacholine Chloride ● ● ● ●
Methadone Hydrochloride ● ● ● ● ●










Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































Methohexital Sodium ● ● ●
Methotrexate Sodium ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Methoxsalen ● ● ● ● ●
Methoxy Polyethylene Glycol-Epoetin Beta ● ● ● ● ●
Methylphenidate ● ● ● ● ●
Methylphenidate Hydrochloride ● ● ● ● ●
Methysergide Maleate ● ● ●
Metoclopramide Hydrochloride ● ●
Metolazone ●
Metoprolol Succinate ● ● ●
Metoprolol Tartrate ● ● ● ●
Metronidazole ● ●
Mexiletine Hydrochloride ● ● ● ●
Midazolam Hydrochloride ● ● ● ● ● ●
Midodrine Hydrochloride ● ●
Mifepristone ● ● ● ● ●
Milnacipran Hydrochloride ● ● ●
Minoxidil ● ● ● ● ●
Mirtazapine ● ● ●
Misoprostol ● ● ● ● ●
Mitomycin ● ● ● ● ●
Mitotane ● ●
Mitoxantrone Hydrochloride ● ● ● ● ● ● ● ●
Modafinil ●
Moexipril Hydrochloride ● ●
Molindone Hydrochloride ● ● ● ●
Moricizine Hydrochloride ● ● ●
Morphine Sulfate ● ● ● ●
Morphine Sulfate/Naltrexone Hydrochloride ● ● ● ● ●
Moxifloxacin Hydrochloride ● ● ●
Muromonab-CD3 ● ● ● ● ● ●
Mycophenolate Mofetil ● ● ● ● ● ●
Mycophenolate Sodium ● ● ● ● ● ●
Nabumetone ● ● ● ● ●
Nadolol ● ● ● ● ● ●
● ● ●
Naltrexone Hydrochloride ● ● ●
Nandrolone Decanoate ● ● ● ●
Naproxen ● ● ● ● ●
Naproxen Sodium/Sumatriptan Succinate ● ● ● ● ●
Natalizumab ● ● ● ● ●
Nefazodone Hydrochloride ● ● ● ● ●
Nelarabine ● ●
Neomycin ● ● ● ● ● ● ●
Nevirapine ● ● ● ● ● ●
Nilotinib Hydrochloride ● ● ● ●
Nilutamide ● ● ●
Nimodipine ●
Nitroprusside Sodium ● ● ●
Norepinephrine Bitartrate ●
Norfloxacin ● ● ●
Nortriptyline Hydrochloride ● ● ●
Ofloxacin ● ● ●
Olanzapine ● ● ● ●
Olanzapine Pamoate (inj) ● ● ● ● ● ● ●
Olmesartan Medoxomil ● ●
Omalizumab ● ● ● ● ●
OnabotulinumtoxinA ● ● ● ● ● ● ●
Ondansetron Hydrochloride ● ●
Oprelvekin ●
Oxaliplatin ●
Oxandrolone ● ● ● ●
Oxaprozin ● ● ● ● ●
Oxycodone Hydrochloride ● ● ● ● ●
Oxymetholone ● ● ● ●
Oxymorphone Hydrochloride ● ● ● ● ●
Oxytocin ●
Paclitaxel ● ● ● ● ● ● ● ●
Paclitaxel Protein-Bound ● ● ● ●





Table 2: Compiled Black Box Warning Table (continued)











































































































































































































































































































































































Paroxetine Hydrochloride ● ● ●
Paroxetine Mesylate ● ● ●
Pazopanib Hydrochloride ● ●
Peginterferon Alfa-2a ● ● ● ● ● ● ●
Peginterferon Alfa-2b ● ● ● ● ● ● ●
Pemoline ● ● ● ●
Penicillamine ●
Penicillin G Benzathine ● ● ●
●
Pentostatin ● ● ● ● ● ● ●
Peramivir ● ● ●
Perflutren Lipid Microsphere ● ● ● ●
Perflutren Protein Type A Microsphere ● ● ● ●
Pergolide Mesylate ● ● ● ● ●
Perindopril Erbumine ● ●
Perphenazine ● ● ● ●
Phenelzine Sulfate ● ● ●
Phenylephrine Hydrochloride ●
● ● ● ●
Phenytoin Sodium ●
Phytonadione ● ● ● ●
Pimecrolimus ● ● ● ●
Pimozide ● ● ● ●
Pioglitazone Hydrochloride ● ● ● ●
Piroxicam ● ● ● ● ●
Polymixin B Sulfate ● ● ● ● ● ● ●
Polysaccharide Iron Complex ● ● ●
Polythiazide/Prazosin Hydrochloride ● ●
Polythiazide/Reserpine ● ●
Pooled Plasma (human) SD Treated ● ● ●
Potassium Chloride ●
Potassium Iodide (see Iodine) ● ● ● ●
Pramlintide Acetate ● ● ●
Prasugrel Hydrochloride ● ● ● ● ●
Primaquine Phosphate ●
Procainamide Hydrochloride ● ● ● ●
Procarbazine Hydrochloride ●
Prochlorperazine ● ● ● ●
Progesterone ● ● ● ● ● ● ● ●
Promethazine Hydrochloride ● ● ● ●
Propafenone Hydrochloride ● ●
Propoxyphene Hydrochloride ● ● ● ● ● ● ●
Propoxyphene Napsylate ● ● ● ● ● ● ●
Propranolol Hydrochloride ● ● ●
Protamine Sulfate ● ● ● ● ● ● ●
Protriptyline Hydrochloride ● ● ●
Pyridostigmine Bromide ● ● ●
Pyrimethamine/Sulfadoxine ● ● ●
Quetiapine Fumarate ● ● ● ● ● ●




Ractopamine Hydrochloride ● ●
Raloxifene Hydrochloride ● ● ● ● ●
Ramipril ● ●
Ranitidine ●
Rasburicase ● ● ● ● ●
Rho(D) Immune Globulin ● ● ● ● ●
Ribavirin ● ● ● ● ● ● ● ●
RimabotulinumtoxinB ● ● ● ●
Risperidone ● ● ● ●
Ritonavir ● ●
Rituximab ● ● ● ● ● ● ● ●
Rosiglitazone Maleate ● ● ● ●
Salmeterol Xinafoate ● ●
Salsalate ● ● ● ● ●
Saquinavir ●
Selegiline ● ● ●




Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































Sertraline Hydrochloride ● ● ●
Sirolimus ● ● ● ● ● ● ● ●
Smallpox Vaccine ● ● ● ● ● ● ● ●
Sodium Chloride ●
● ● ●
Sodium Oxybate ● ● ● ● ●
● ● ● ●
Sodium Polystyrene Sulfonate CATION-EXCHANGE RESIN
Soft (Hydrogel) Contact Lens Products ●
Sotalol Hydrochloride ● ● ●
Soybean Oil (See Fat Emulsion) ● ● ●
● ● ●
Spironolactone ● ●
Stanozolol ● ● ● ●
Stavudine ● ● ● ● ●
Streptomycin ● ● ● ● ● ● ● ● ●
Streptozocin ● ● ● ● ● ●
Succinylcholine Chloride ● ● ● ● ●
Sulindac ● ● ● ● ●
Tacrolimus ● ● ● ● ● ● ●
Tamoxifen Citrate ● ● ● ● ● ●
Telavancin Hydrochloride ● ● ●




Teniposide ● ● ● ●
Tenofovir Disoproxil Fumarate ● ● ● ● ●
Teriparatide ● ● ● ●
Testosterone (gel) ● ●
Tetanus Toxoid ●
Tetrabenazine ● ● ●
Thalidomide ● ● ● ● ● ● ●
Thioridazine Hydrochloride ● ●
Thiothixene ● ● ● ●
Thrombin, Bovine ● ●
Thyroid ● ●
Ticlopidine Hydrochloride ● ● ●
Timolol Maleate ● ● ●
Tinidazole ● ●
Tinzaparin Sodium ● ● ● ●
Tipranavir ● ● ● ●
Tobramycin ● ● ● ● ● ● ●
Tocainide Hydrochloride ● ● ● ● ● ● ●
Tocilizumab ● ● ● ● ●
Tolcapone ● ● ● ● ● ●
Tolmetin Sodium ● ● ● ● ●
Tolvaptan ● ● ● ● ●
Topotecan Hydrochloride ● ● ● ●
Tositumomab ● ● ● ● ●
Trandolapril ● ●
Trandolapril/Verapamil Hydrochloride ● ●
Tranylcypromine Sulfate ● ● ●
Trastuzumab ● ● ● ● ●
Trazodone Hydrochloride ● ● ●
Tretinoin ● ● ● ● ● ● ● ● ●
Triamterene ● ● ●
Triazolam ●
● ●
Trifluoperazine ● ● ● ●
Trimetrexate Glucuronate ●
Trimipramine Maleate ● ● ●
Trovafloxacin Mesylate ● ●
Urokinase ● ●
Vaccinia Immune Globulin, Human ● ● ● ●
Valdecoxib ● ●
Valganciclovir Hydrochloride ● ● ● ●
Valproate Sodium ● ● ● ● ● ●
Sodium Nitroprusside (see Nitroprusside 
Sodium)
Sodium Phosphate Dibasic/Sodium Phosphate 
Monobasic





Table 2: Compiled Black Box Warning Table (continued)










































































































































































































































































































































































Valproic Acid ● ● ● ● ● ●
Valsartan ● ●
Varenicline ● ● ● ●
Varicella-Zoster Immune Globulin ● ● ●
Vecuronium Bromide ●
Venlafaxine Hydrochloride ● ● ●
Vigabatrin ● ● ● ●
Vinblastine Sulfate ● ●
Vincristine Sulfate ● ●
Vinorelbine Tartrate ● ● ● ●
Warfarin Sodium ● ● ●
Water (Sterile Water) ●
Zalcitabine ● ● ● ● ● ●
Zaleplon ●
Zanamivir ●
Ziconotide ● ● ● ●
Zidovudine ● ● ● ● ● ●
Ziprasidone Hydrochloride ● ● ● ●























































A Caution or avoidance with select patient populations,indications, or clinical situations
B 
Administration or monitoring instructions
C 
Caution or avoidance of select concurrent medications, treatments, or substance use
D 
Use reserved for select patient populations, indications, or clinical situations





















Figure 17: BBW for sodium polystyrene sulfonate in DailyMed. 
Figure 16: Section of SPL for erlotinib hydrochloride in DailyMed. DailyMed lists erlotinib as 
having a black box warning (red box), however, the black box warning is empty. 
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Table 3: Frequency of black box warning classifications





















Total numer of drug BBWs 635






Concurrent Item Restriction 
C
156






 Caution or avoidance with select patient populations,indications, or clinical situations
B 
Administration or monitoring instructions
C 
Caution or avoidance of select concurrent medications, treatments, or substance use
D  
Use reserved for select patient populations, indications, or clinical situations
Effects on Organ Systems Frequency of BBWs
Other Effects Frequency of BBWs
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551 514 500 536 635
Combination drugs with a BBW 95 79 71 28 101
N/A N/A N/A 63 N/A
84 121 135 99 0
7 N/A N/A 7 N/A
23 83 94 2 N/A
54 38 41 90 N/A
A
 See methods section
B
 See introduction section
BBW drugs absent  from database due to listing as 
bolded warning only 
B
BBW drugs absent from database due to listing without a 
BBW  even though drug present in database
BBW drugs absent from database due to complete 




Total number of drugs with a BBW present in each 
database
Total number of drugs with a BBW present on the 
collective BBW list but absent  from each respective 
database











551 514 500 536
416 416 416 416
54 69 58 80
26 18 9 35
55 11 17 5
84 121 135 99
33 77 71 83
18 26 35 9
33 18 29 7
A
 Figures for BlackBoxRx include combination drugs not listed as described in methods section 
BBW drugs absent from database as well as 2 of the 
other databases
BBW drugs absent from database as well as 1 of the 
other databases
BBW drugs absent from only from this database
Total number of BBW drugs present in each 
database:
Total number of BBW drugs present on collective 
BBW list but absent from each database:
BBW drugs present in database as well as all 3 other 
databases
BBW drugs present in database as well as 2 of the 
other databases
BBW drugs present in database as well as 1 of the 
other databases











Figure 19: DailyMed accompanying black box warning for majority of metformin and metformin 
containing combination drugs. 
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Figure 20: In DailyMed, sections of SPLs for five different formulations of metformin 
hydrochloride demonstrating that these do not carry a black box warning. 
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Figure 21: In DailyMed, portion of SPL for one formulation of metformin hydrochloride and its BBW 






Figure 22: In DailyMed, black box warning for metformin hydrochloride/pioglitazone 






Figure 23: Facts & Comparisons BBW list with auto fill feature noted at top. As an example, 
typing “metopro” yields a dropdown selection of  three potential drug/drug combos. 
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Figure 24: BBW for chloramphenicol as presented in BlackBoxRx (above) and DailyMed (below) 
as an example of how BlackBoxRx truncates BBW information in bullet point format. 
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